Blood Cancer Therapeutics: Global Markets to 2023 - Highly Sensitive Tests to Detect Minimal Residual Disease - ResearchAndMarkets.com
The "Blood Cancer Therapeutics: Global Markets to 2023" report has been added to ResearchAndMarkets.com's offering.
This report organizes information from diverse sources into a comprehensive report that includes an overview, market dynamics, disease type, leading blockbuster drug profiles, regulations, reimbursement and patents. It analyzes prevailing blood cancer treatment guidelines in different geographic regions.
The scope of the blood cancer therapeutic market is restricted to three disease areas: leukemia, lymphoma and multiple myeloma. Leukemia is classified into four sub-segments: chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
This report includes an overview of the global market scenario for blood cancer treatments with base year data from 2017, estimations for 2018 and forecasts for 2019 to 2023, using CAGR projections. Market data in value terms is provided at global, regional and country levels for disease areas.
- Rising Incidence of Blood Cancer
- Highly Sensitive Tests to Detect Minimal Residual Disease
- Rising Government & Private Funding for Cancer Treatment
- Absence of Screening Programs for Early Detection
- Low Awareness
Key Topics Covered
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market Overview
Chapter 4 Market Dynamics and Technology Background
Chapter 5 Market Breakdown by Disease Type
Chapter 6 Blood Cancer Treatment Regimens
Chapter 7 Market Breakdown by Region
Chapter 8 Pipeline Analysis
Chapter 9 Regulatory and Reimbursement Structure
Chapter 10 Competitive Landscape and Key Developments
Chapter 11 Company Profiles
- AbbVie Inc
- Amgen Inc.
- Astrazeneca PLC
- Boehringer Ingelheim Pharmaceuticals Inc.
- Bristol-Myers Squibb Co.
- Celgene Corp.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences Inc.
- Glaxosmithkline PLC
- Janssen Global Services LLC
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Surface Oncology
- Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/64s6l6/blood_cancer?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20190108005566/en/